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CD138 (Syndecan1) is highly expressed on multiple myeloma (MM) cells. In this study, we 
examined the anti-MM effect of murine/human chimeric CD138-specific monoclonal antibody 
(mAb) nBT062 conjugated with highly cytotoxic maytansinoid derivatives in vitro and in vivo. 
These agents significantly inhibited growth of CD138-positive MM cell lines and primary 
tumor cells from MM patients, without cytotoxicity against peripheral blood mononuclear cells 
from healthy volunteers. In MM cells, they induced G2/M cell cycle arrest followed by 
apoptosis associated with cleavage of PARP and caspase-3, -8 and -9. Non-conjugated 
nBT062 completely blocked cytotoxicity induced by nBT062-maytansinoid conjugate, 
confirming that binding is required for inducing cytotoxicity. Moreover, nBT062-maytansinoid 
conjugates blocked adhesion of MM cells to bone marrow stromal cells (BMSCs). Co-culture 
of MM cells with BMSCs, which protects against dexamethasone-induced death, had no 
impact on the cytotoxicity of the immunoconjugates. Importantly, nBT062-SPDB-DM4 and 
nBT062-SPP-DM1 significantly inhibited MM tumor growth in vivo in both human multiple 
myeloma xenograft mouse models and in SCID-human bone grafts (SCID-hu mouse model). 
These studies provide the preclinical framework supporting evaluation of 
nBT062-maytansinoid derivatives in clinical trials to improve patient outcome in MM. 
 
Introduction 
The cell surface proteoglycan CD138 (Syndecan1) is an integral membrane protein acting as 
a receptor for the extracellular matrix. Within the normal human hematopoetic compartment, 
CD138 is expressed exclusively on differentiated plasma cells and is a primary diagnostic 
marker of multiple myeloma (MM)1. Several monoclonal antibodies (mAbs) (i.e., B-B4, 
BC/B-B4, B-B2, DL-101, 1 D4, MI15, 1.BB.210, 2Q1484, 5F7, 104-9, 281-2) specific for 
CD138 have been reported.  B-B4, 1D4 and MI15 Abs, which bind to similar or 
closely-related epitopes, recognize both the intact CD138 molecule and the core protein (with 
the heparin sulphate chains removed), and target the same or closely related epitopes. B-B4 
preferentially binds to membrane bound versus soluble CD138.2 It is a murine IgG1 
monoclonal antibody that binds to a linear epitope between residues 90-95 of the core protein 
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on human syndecan-1. Consistent with the expression pattern of CD138, B-B4 strongly 
reacts with the MM cell line RPMI 8226, but not with endothelial cells. Moreover, B-B4-saporin 
immunotoxin is highly cytotoxic to RPMI8226 cells.3  
Here we demonstrate the anti-tumor efficacy of three novel anti-CD138 
antibody-maytansinoid conjugates, nBT062-SMCC-DM1, nBT062-SPDB-DM4 and 
nBT062-SPP-DM1, which vary in the linkage between the maytansinoid moiety and mAb.  
The nBT062-SMCC-DM1 linkage contains a thioether bond which is not cleavable by 
disulfide exchange, whereas the nBT062-SPDB-DM4 and nBT062-SPP-DM1 conjugates 
contain disulfide linkages which can be cleaved by disulfide exchange, resulting in liberation 
of active maytansinoid agent. The anti-CD138 antibody nBT062 is a murine/human chimeric 
form of B-B4, with identical specificity for CD138 as the parent murine antibody. The observed 
preclinical anti-tumor activity of the nBT062-maytansinoid conjugates provides the framework 
for clinical development of these agents to improve patient outcome in MM. 
 
Materials and Methods 
Detailed information pertinent to tumor cell lines and primary tumor cells from MM patients; 
Growth inhibition assay and proliferation assay; cell cycle profiling; detection of apoptosis; 
immunoblotting; immunofluorescence: adheision assay; sCD138-ELISA; human MM 
xenograft mouse model and SCID-hu mouse model are included as supplemental information 
on the Leukemia website. The statistical significance of differences observed in drug-treated 
versus control cultures was determined using Dunn’s multiple comparison tests in vivo study. 
The minimal level of significance was P < 0.05. Survival was assessed using Kaplan-Meier 
curves and log-rank analysis. 
 
Results 
Expression of CD138 in MM cell lines   
We first evaluated the expression of CD138 in MM1S, OPM1, OPM2, RPMI8226, DOX40, 
MM1R, LR5, U266, MOLP-8, and INA-6 MM cell lines. Western blot analysis (Supplemental 
Figure 1A ) , Immunofluorescence (Supplemental Figure 1B ) and flow-cytometric analysis 
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(Fig.1) demonstrated that CD138 is expressed on all MM cell lines tested except LR5 and 
Dox40.  
Selective cytotoxicity of nBT062-maytansinoid conjugate against CD138-positive MM 
cell lines in vitro. 
The in vitro cytotoxicity of the anti-CD138 antibody nBT062 conjugated with maytansinoids 
DM1 and DM4 was next evaluated. The nBT062 conjugates tested vary in the chemical linker 
used to attach the maytansinoid molecule to the Ab. The chemical structures of 
nBT062-SMCC-DM1, nBT062-SPDB-DM4, and nBT062-SPP-DM1 are shown in Fig 2A. 
nBT062-SMCC-DM1, nBT062-SPDB-DM4, and nBT062-SPP-DM1 (3-354 ng/mL) 
demonstrated cytotoxicity against OPM1 and RPMI8226 cells (CD138-Positive) in a 
dose-dependent fashion. In contrast, minimal cytotoxicity was noted in CD138-negative cell 
lines (Fig.2B). Importantly, these agents were also cytotoxic against primary tumor cells from 
MM patient isolated by negative selection, with IC50 values of approximately 1nM (111-442 
ng/mL) at 48 h (Fig.2C). However, no cytotoxicity was observed against primary tumor cells 
from MM patients isolated by CD138-positive selection (Supplemental Fig.2A) suggesting that 
CD138-binding is important for immunoconjugate-mediated cytotoxicity and that binding is 
blocked by the anti-CD138 antibody used in the positive selection procedure. Indeed, 
non-conjugated nBT062 completely abrogated cytotoxicity induced by nBT062-SPDB-DM4 in 
OPM2 cells (Supplemental Fig.2B). Importantly, the maytansinoid conjugates did not induce 
cytotoxicity in PBMCs from healthy volunteers at concentrations as high as 12 nM (1770 
ng/mL), further demonstrating the specificity of these agents for CD138-positive cells. 
(Fig.2D) 
CD138-specific immunoconjugates induce cell cycle arrest, followed by caspase and 
PARP cleavage in OPM1 cells 
Maytansinoids are anti-mitotic agents that inhibit tubulin polymerization and microtubule 
assembly, and the maytansinoids DM1 and DM4 induce growth arrest tumor cells in the G2/M 
phase of the cell cycle4.  We therefore next examined the cell cycle profile of OPM1 cells 
after nBT062-SMCC-DM1, nBT062-SPDB-DM4, and nBT062-SPP-DM1 treatment.  As 
shown in Fig.3A, treatment of OPM1 cells with 1000 ng/mL of these three agents for 24h 
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induced a time-dependent increase in G2/M phase cells. nBT062-SPDB-DM4 had the most 
potent effect.  
To determine whether the cytotoxicity induced by these agents is via an apoptotic mechanism, 
we carried out Apo 2.7 staining and assessed cleavage of caspases and PARP. Treatment of 
OPM1 cells with the maytansinoids significantly increased Apo 2.7-positive cells in a time 
dependent fashion (Fig. 3B), associated with induction of cleavage of caspase-8, caspase-9, 
caspase-3, and PARP (Fig. 3C, left and middle panel). Conversely, the pan-caspase inhibitor 
z-VAD-fmk (50μM) blocked nBT062-SPDB-DM4-induced caspase and PARP cleavage in 
OPM1 cells (Fig. 3C, right panel).  These results indicate that cytotoxicity triggered by these 
maytansinoid conjugates is mediated via caspase-dependent (both intrinsic and extrinsic) 
apoptotic pathways.  
The immunoconjugates overcome the protective effects of growth factors and BMSC. 
Since IL-6 and IGF-1 promote MM cell survival by inhibiting apoptosis, we next examined 
whether these immunoconjugates can overcome this protective effect.  Neither IL-6 nor 
IGF-1 was able to block the cytotoxicity induced by these conjugates (Fig. 4A and B and data 
not shown). We also examined the cytotoxicity triggered by the conjugates in the context of 
BMSCs. Although BMSCs significantly inhibited dexamethasone-induced growth inhibition, 
they were not able to protect against immunoconjugate-induced cytotoxicity in OPM1 cells 
(Fig. 4C). 
nBT062-SPDB-DM4 and nBT062-SPP-DM1 inhibit adhesion of MM1S cells to BMSCs. 
Many studies have revealed that Syndecan-1 (CD138) mediates interactions between cells 
and extracellular matrix proteins to function as an adhesion molecule5-7 8.  We therefore next 
evaluated whether these conjugates could inhibit MM cell adhesion to BMSCs. Pretreatment 
of BMSCs with nBT062-SPDB-DM4 had only a modest inhibitory effect on MM1S cell 
adhesion to BMSCs; however, pretreatment of MM1S cells with nBT062-SPDB-DM4 almost 
completely blocked MM1S cell adhesion to BMSCs, suggesting that CD138 mediates MM cell 
adhesion, which is blocked by immunoconjugates(Fig.4D). 
Soluble CD138 levels are greater in MM cell culture supernatants than in MM patient 
BM plasma 
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sCD138 can be cleaved by the action of secretases 9 and released from the cell surface, 
which may inhibit binding of anti-CD138 immunoconjugates to the MM cell surface. We 
therefore next measured sCD138 levels in MM cell culture supernatants and BM plasma from 
MM patients. As shown in Figure 5, soluble CD138 concentrations in BM plasma from MM 
patients were lower than levels in culture supernatants from RPMI8226 and OPM1 MM cells. 
Since the immunoconjugates are cytotoxic against both RPMI8226 and OPM1 MM cells, 
these results suggest that levels of circulating sCD138 in MM patient BM plasma will not 
inhibit binding of anti-CD138 immunoconjugate to MM cells. 
nBT062-maytansinoid conjugates inhibit tumor growth in a human MM xenograft 
model and SCID-hu model. 
The in vivo efficacy of nBT062-SPDB-DM4, nBT062-SMCC-DM1, and nBT062-SPP-DM1 
was next evaluated in SCID mice bearing established CD138-positive MOLP-8 human MM 
cells. A single intravenous administration of the immunoconjugates caused significant 
dose-dependent tumor growth inhibition and tumor regression at concentrations that were 
well tolerated, evidenced by stable body weight (Fig.6A). nBT062-SPDB-DM4 was the most 
active conjugate tested in this model. In addition, weekly dosing of the nBT062-SMCC-DM1 
conjugate (6 doses of 13.8 mg/kg) completely blocked tumor growth during the dosing period.   
In a second study, the importance of antigen-targeting for the anti-tumor activity of 
nBT062-SPDB-DM4 and nBT062-SPP-DM1 was evaluated by comparing the activity of 
unconjugated maytansinoid DM4, native unmodified nBT062 antibody, and a non-targeting 
(irrelevant) huIgG1-SPDB-DM4 conjugate.  Treatment with a single bolus IV injection of 
nBT062-SPDB-DM4 and nBT062-SPP-DM1 (at a dose of approximately 14 mg/kg) inhibited 
the growth of the MOLP-8 xenografts (Fig 6 B); nBT062-SPDB-DM4 was the most active 
conjugate.  In contrast, minimal anti-tumor activity was observed with free DM4, nBT062 
antibody, and the non-binding DM4 conjugate, demonstrating the importance of specific 
targeting by the nBT062-maytansinoid conjugates for their in vivo efficacy. 
The efficacy of nBT062-SPDB-DM4 and nBT062-SPP-DM1 was also examined in mice 
bearing subcutaneous fluorescent OPM1 MM cells (OPM1GFP+) (Supplemental Fig.3). 
Treatment of OPM1 MM tumor-bearing mice with nBT062-SPDB-DM4 (0.176 mg conjugate 
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/mouse; approximately 6 mg/kg) significantly inhibited MM tumor growth compared with 
control animals treated with control vechicle (Dunn’s multiple comparison test; control vehicle 
vs. nBT062-SPDB-DM4 at 10 days post-treatment: P<0.01, Fig. 6C and Supplemental 
Fig.4A).  Similar to the results observed in the MOLP-8 model, nBT062-SPP-DM1 was not 
as effective as nBT062-SPDB-DM4 (Dunn’s multiple comparison test; nBT062-SPP-DM1 vs. 
nBT062-SPDB-DM4 at 10 days post-treatment: P<0.05, Fig. 6B). Kaplan-Meier and log-rank 
analysis revealed a mean overall survival (OS) of 13.6 days in the control cohort (95% 
confidence interval [CI], 10-19 days) versus 26 days (95% CI, 23-42 days) in groups treated 
with nBT062-SPDB-DM4 (Supplemental Fig.4B). Ex vivo analysis of tumors excised from 
mice showed significantly increased apoptosis in the mice treated with nBT062-SPDB-DM4 
versus control cohorts (Supplemental Fig.5) Importantly, Treatment with these agents did not 
affect body weight. 
In order to examine the activity of nBT062-SPDB-DM4 and nBT062-SPP-DM1 on MM cells 
growth in the context of the human BM microenvironment in vivo, we next used a SCID-hu 
model in which IL-6 dependent INA-6 cells are directly injected into a human bone chip 
implanted in SCID-mice. These SCID-hu mice bearing human bones engrafted with INA-6 
cells were treated via tail vein with nBT062-SPDB-DM4, nBT062-SPP-DM1 or vehicle alone 
weekly for 7 weeks. The serum shuIL-6R levels released by INA-6 cells reflects tumor burden 
in this model. As shown in Fig. 6E, nBT062-SPDB-DM4 and nBT062-SPP-DM1 treatment 
caused significant inhibition of tumor growth compared with vehicle control. 
Bystander killing  
Antibody-maytansinoid conjugates similar to nBT062-SPDB-DM4 have been shown to be 
able to kill antigen-negative cells proximal to antigen-positive tumor cells (bystander killing)10.  
To determine whether nBT062-SPDB-DM4. mediates bystander killing, CD138-positive 
OPM2 cells and CD138-negative Namawla cells cultured separately or as a mixture were 
treated with nBT062-SPDB-DM4 for 120 hours.  While nBT062-SPDB-DM4 was inactive 
against CD138-negative Namalwa cells cultured alone, significant killing of the CD138- 
negative cells by nBT062-SPDB-DM4 was observed when mixed with CD138-positive OPM2 
cells. (Supplemental Fig.6) 





CD138 is highly expressed on MM cells and is involved their development and/or proliferation, 
making CD138 an attractive therapeutic target. CD138 may be a suitable target for an 
antibody-directed immunoconjugate, although the use of a murine antibody in prior studies 
has precluded their clinical development11. In the current study, we have evaluated the 
anti-tumor activity of a series of immunoconjugates comprised of the murine/human chimeric 
anti-CD138 antibody nBT062 conjugated with potent cytotoxic maytansinoid moieties. The 
immunoconjugates tested, nBT062-SMCC-DM1, nBT062-SPDB-DM4 and 
nBT062-SPP-DM1, vary in the nature of the disulfide linkage that attaches the cytotoxic agent 
to the antibody. 
A series of MM cell lines were tested for CD138 expression using flow cytometry and 
immunoblotting, and these cell lines were used for the evaluation of the activity of the nBT062 
conjugates. The nBT062-maytansinoid conjugates were highly active against MM tumor cell 
lines and patient MM cells that expressed CD138, with nBT062-SPDB-DM4 being the most 
potent of the three conjugates tested.  Importantly, little or no cytotoxicity was observed upon 
treatment of CD138-negative cell lines and peripheral blood mononuclear cells from healthy 
volunteers, suggesting that the immunoconjugates are selective for CD138-expressing cells. 
In vivo studies with MM tumor xenografts in immunocompromised mice showed that 
nBT062-SPDB-DM4 is the most efficacious of the conjugates tested, and that the anti-tumor 
activity in mice is dependent on specific-targeting of the nBT062 conjugate.   
In vitro mechanistic studies also demonstrated that nBT062-SMCC-DM1, 
nBT062-SPDB-DM4, and nBT062-SPP-DM1 inhibited the proliferation of MM cells by 
inducing G2/M cell cycle arrest followed by apoptotic cell death, evidenced by 
dose-dependent cleavage of caspases and PARP, as well as increased APO2.7-positive cells.  
We and others have previously reported that IL-6 triggers proliferation of MM cells and 
protects against dexamethasone-induced apoptosis via activation of PI3-K/Akt, MEK/ERK 
and JAK2/STAT3 signaling cascades12-14.  IGF-I also promotes MM cell proliferation and 
survival; however, neither IL-6 nor IGF-I protect against nBT062-SPDB-DM4-induced 
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cytotoxicity, suggesting that these immunoconjugates can overcome the protective effects of 
these cytokines in the BM milieu.  We further evaluated the impact of the BM 
microenvironment on the anti-tumor activity of these immunoconjugates using MM cells 
co-cultured with isolated BMSCs.  While co-culture with BMSCs significantly inhibits the 
anti-proliferative effects of dexamethasone, there was no impact on the cell killing activity of 
the nBT062-maytansinoid conjugates.    
Previous studies have demonstrated that IL-6 can bind to the soluble heparin sulfate side 
chain of proteoglycans like CD138 (syndecan-1).  These heparin sulfate proteoglycans can 
function as co-receptors for the growth factors, thereby leading to increased cell growth, 
survival, and adhesion15-17.  Within the BM milieu,  induction of IL-6 secretion from BMSCs 
is triggered by direct MM cell-BMSC contact mediated by adhesion molecules such as 
integrins and CD44 on the surface of MM cells 8,18 19.  Interestingly, nBT062-SPDB-DM4 and 
nBT062-SPP-DM1 can block the adhesion of MM cells to BMSCs, suggesting that the 
immunoconjugates may also function to overcome cell adhesion–mediated drug resistance 
(CAM-DR) to conventional therapies. 
Our experiments suggest that free nBT062 can block the cytotoxicity of nBT062-SPDB-DM4 
confirming selectivity. However antibody-maytansinoid conjugates similar to 
nBT062-SPDB-DM4 can have potent cell killing effects not only on antigen-positive cells, but 
also on antigen-negative cells in close proximity to the tumor cells. Importantly, the presence 
of antigen-positive cells is required for this so-called bystander killing. A general mechanism 
of cytotoxicity for disulfide bond-linked antibody-maytansinoid conjugates includes binding of 
the conjugate to target cells, internalization into the target cell, cleavage of the conjugate 
disulfide bond, and release of the maytansinoid moiety, which is then capable of killing the 
target and nearby non-target cells.  We carried out the studies which demonstrated 
bystander killing of CD138-negative Namawla cells in the presence of CD138-positive OPM2 
cells with nBT062-SPDB-DM4. (Supplemental Fig.5) Bystanders killing of non-target cells in 
close proximity to MM cells would be expected to 1) provide an advantage for the eradication 
of tumor cells that heterogeneously express CD138, such as the putative CD138 negative 
myeloma stem cells20, 2) kill tumor stroma cells, thereby destroying the tumor 
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microenvironment and/or 3) prevent selection of BT062-resistant tumor cells. 
The enzyme responsible for the shedding of CD138 (Syndecan-1) from the cell surface has 
not been identified.  The proteolytically released extracellular domain (ectodomain) of 
Syndecan-1 retains its biologically active heparin sulfate chains.  Therefore shed sCD138 in 
the BM plasma of MM patients could interfere with the function of an nBT062-maytansinoid by 
blocking access to the surface of MM tumor cells or by increasing the plasma clearance of the 
conjugate.  Importantly, we showed that the level of sCD138 in MM patient BM plasma is 
less than in MM cell line supernatants, where the immunoconjugates show potent cell killing 
activity. Therefore sCD138 levels in MM patient BM plasma should not interfere with binding 
of immunoconjugates.   
In summary, nBT062-SMCC-DM1, nBT062-SPDB-DM4, and nBT062-SPP-DM1 have in vitro 
and in vivo anti-tumor activity against CD138-positive MM cells and can overcome the 
protective effects of cytokines, BMSCs, and CAM-DR.  Our results provide the preclinical 
framework of clinical trials for the most potent of the immunoconjugates tested, 
nBT062-SPDB-DM4 (to be referred to as BT062), to improve patient outcome in MM.  
 
Figure Legends 
Figure 1  
Expression of CD138 in MM cell lines: CD138 expression in MM cell lines was determined by 
flow cytometry. 
Figure 2  
nBT062-maytansinoid conjugates have selective cytotoxicity toward CD138-positive cell 
lines.(A) Structure of nBT062-maytansinoid conjugates. nBT062-SMCC-DM1 contains a 
thioether-linkage that is not a substrate for disulfide exchange reactions. nBT062-SPDB-DM4 
and nBT062-SPP-DM1 contain hindered disulfide linkages. (B) CD138-positive OPM1 (  ) 
and RPMI8226 (  ), and CD138-negative MM cell lines DOX40 (  ) and MM1S (  ) 
were treated with nBT062-SMCC-DM1, nBT062-SPDB-DM4 and nBT062-SPP-DM1 for the 
indicated time periods.(C) Primary tumor cells from MM patients were isolated by negative 
selection and  cultured with nBT062-SMCC-DM1 (  ), nBT062-SPDB-DM4 (  ), and 
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nBT062-SPP-DM1 (  ) for 48h. (D) PBMCs isolated from normal donors were cultured 
with nBT062-SMCC-DM1 (  ), nBT062-SPDB-DM4 (  ), nBT062-SPP-DM1 (  ) for 
72h, with OPM1 cells (  ) serving as a positive control. Cell viability (B-D) was assessed by 
MTT assay, and the data shown represent mean ±SD of triplicate cultures, expressed as 
percentage of untreated controls. 
Figure3  
nBT062-maytansinoid conjugates induce G2/M growth arrest, followed by 
caspase-dependent apoptosis. (A) Cell cycle analysis: OPM1 cells were treated with nBT062- 
maytansinoids for 0, 12, and 24h, and then subjected to propidium iodide (PI) staining. (B) 
OPM1 cells were cultured with nBT062-maytansinoid (885ng/mL) for 0 hours (  ), 24h 
(  ), 48h (  ) and 72h (  ). Apoptotic cells were assessed by Apo 2.7 staining using 
flow cytometric analysis. (C) OPM1 cells were cultured with nBT062-SPDB-DM4 (885ng/mL) 
for the indicated time periods (left panel). Cells were treated with increasing concentrations of 
nBT062-SPDB-DM4 (0-885ng/mL) for 48h (middle panel). OPM1 cells were pre-incubated 
with Z-VAD-fmk (50 μmol/L) for 60 minutes prior to treatment with24h nBT062-SPDB-DM4 
(right panel). Total cell lysates were subjected to immunoblotting using anti–caspase-3, -8, -9, 
PARP, and α-tubulin Abs. FL indicates full-length protein and CL indicates cleaved protein, 
respectively.  
Figure4  
Effect of growth factors and BMSCs on the sensitivity of MM cells to nBT062-maytansinoid 
immunoconjugates OPM1 cells were cultured for 48h with control media (  ); or with 
nBT062-SPDB-DM4 at 55ng/ml (  ), 111ng/ml (  ), 221ng/ml (  ), in the presence or 
absence of (A) IL-6 (1 and 10ng/ml), (B) IGF-1(10 and 50 ng/mL) or (C) BMSCs. In BMSC 
co-culture, cells were incubated for 48h with control media (  ), and with 250nM (  ), 
500nM (  ), 1000nM (  ) dexamethasone, in the presence or absence of BMSCs for 48h, 
as a positive control for drug resistance. DNA synthesis was determined by measuring 
[3H]-thymidine incorporation during the last 8 h of 72h cultures. Data represent means (±SD) 
of triplicate cultures. (D) MM1S cells and/or BMSCs were incubated with control media (  ), 
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nBT062-SMCC-DM1 (  ), nBT062-SPDB-DM4 (  ), and nBT062-SPP-DM1 (  ) at 
885ng/mL for 2 hours prior to adhesion. Adherent cells were assessed by measuring 
[3H]-thymidine (Perkin-Elmer, Boston, MA) uptake. Values represent the mean [3H]-thymidine 
incorporation (cpm) of triplicate cultures.  
Figure5  
Quantification of sCD138 levels in cell culture supernatants from MM cell lines and BM 
plasma of MM patients. 
sCD138 levels in cell culture supernatants from MM1S, RPMI8226, OPM1, and DOX40 MM 
cell lines, as well as plasma from15 MM patient BM, were measured by ELISA. Error bars 
indicate SD (±).  
Figure6  
In vivo efficacy of nBT062-maytansinoid conjugates against human MM xenografts in SCID 
mice. (A) Mice bearing established (approximately 100 mm3) MOLP-8 tumor xenografts were 
treated with a single IV administration at day 11 post-inoculation of PBS (  ), or of 
nBT062-SPDB-DM4, nBT062-SPP-DM1,and nBT062-SMCC-DM1 at doses of 100 (  ), 
250 (  ) and 450 (    ) µg/kg, expressed as linked maytansinoid. One group of mice 
was also treated with five weekly IV injections of nBT062-SMCC-DM1. (B) Mice bearing 
MOLP-8 xenografts were treated on Day 12 with a single IV dose of control vehicle (  ) 
or with 250 µg/kg (linked maytansinoid) of nBT062-SPP-DM1(  ), nBT062-SPBD-DM4 
(    )and huIgG-SPDB-DM4 (  ). Groups were also treated with a single injection of the 
free maytansinoid DM4 (X); at 250 µg/kg and unmodified nBT062 antibody (  ) at 13.8 
mg/kg, an antibody dose equivalent to the amount of antibody in the conjugate treatment 
groups). (C) Mice injected with 5× 106 OPM1GFP+ cells were treated with control vehicle 
(  ), nBT062-SPDB-DM4 (  ) and nBT062-SPP-DM1 (  ). Mean tumor volume 
was calculated as in Material and Methods. Error bars represent SD (±).  (D) SCID-hu mice 
engrafted with INA-6 cells in human bone chip were monitored for tumor growth by serial 
serum measurements of shuIL-6R as a measure of MM cell growth. Mice were treated with 
nBT062-SPDB-DM4(  )  nBT062-SPP-DM1(  ) or vehicle(  ) and the shuIL-6R 
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levels were determined every week. 
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